A 39 Week Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Effect of Fixed Dose Carbidopa/Levodopa/Entacapone 100 mg t.i.d. vs. Immediate Release Carbidopa/Levodopa 25/100 mg (t.i.d.) in Parkinson's Disease Patients Requiring Levodopa
Phase of Trial: Phase III
Latest Information Update: 10 May 2017
At a glance
- Drugs Levodopa/carbidopa; Levodopa/carbidopa/entacapone
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms FIRST-STEP
- Sponsors Novartis
- 15 Mar 2009 Results published in Movement Disorders.
- 26 Aug 2008 Results were presented at the 12th Congress of the European Federation of Neurological Societies.
- 15 Apr 2008 Results were presented at the American Academy of Neurology Annual Meeting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History